Stan Howell
About Stan Howell
Stan Howell is the VP of Strategy & Business Excellence for Cell Therapy Operations at Bristol Myers Squibb, with extensive experience in supply chain management and Lean Six Sigma methodologies.
Title
Stan Howell holds the position of Vice President of Strategy & Business Excellence for Cell Therapy Operations at Bristol Myers Squibb in Summit, New Jersey. In this role, he focuses on overseeing strategic planning and ensuring excellence in business processes within the cell therapy sector.
Company
Bristol Myers Squibb, located in Summit, New Jersey, is the current employer of Stan Howell. Bristol Myers Squibb is known for its innovative work in cell therapy, with Howell playing a crucial role in strategy and business excellence. Previously, he served in key positions at Novartis and Merck, where he led initiatives in global operations and supply chain management.
Education and Expertise
Stan Howell earned an MBA in Business Administration from Eastern University and holds a Bachelor's Degree in Psychology from Millersville University of Pennsylvania. His psychological expertise aids in enhancing team dynamics and leadership effectiveness. Howell's professional background includes extensive experience in Lean Six Sigma methodologies, having served as a Site Lean Six Sigma Leader at Ortho Clinical Diagnostics.
Professional Background
Stan Howell has a diverse professional background spanning multiple leadership roles. At Novartis, he was the VP of Global Operations & Opex Lead/Morris Plains Site Head from 2019 to 2022, where he led a major transformation project that improved operational efficiency and reduced costs. At Merck, Howell served in various senior roles such as Executive Director of Supply Chain Management, Plant Manager, and Strategy Realization Office Leader from 2007 to 2022. He started his Lean Six Sigma journey as a Site Lean Six Sigma Leader at Ortho Clinical Diagnostics.
Achievements
Stan Howell has led several impactful projects throughout his career. At Novartis, he spearheaded a significant transformation project that enhanced operational efficiency and cut down costs. At Bristol Myers Squibb, he played a pivotal role in the successful launch of a new cell therapy product. Additionally, Howell implemented a comprehensive supply chain management system at Merck, streamlining operations across multiple sites. His ongoing work likely involves initiatives to improve patient access to medications and advancing personalized treatments through translational medicine and data analytics.